Why Patients with CLL / SLL Stop BTK Inhibitors - Dr. Kevin Lin ASH 2022 

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) commonly have to stop treatment with Bruton tyrosine kinase (BTK) inhibitors due to adverse events (i.e. side effects). With the introduction of acalabrutinib and zanubrutinib, which have fewer side effects, the hope is patients will be able to stay on BTK inhibitor therapy for longer.
Dr. Kevin Lin from Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and colleagues presented the results at the American Society for Hematology (ASH) Annual Meeting in 2022.
Read the full article on CLL Society's website at: cllsociety.org...
__________________________________________________________________________________________
CLL Society Website: cllsociety.org/
Facebook: / cllsociety
Twitter: / cllsociety
LinkedIn: / cll-society